for locus-specific ChIP

The locus-specific ChIP technologies enable us to explore and identify novel drug targets specifically involved in gene regulation that have not before been discovered by exiting techniques.

Wisteriagen is actively pursuing business collaborations with pharmaceutical and biotech companies which accelerate the discovery and development of revolutionary new drugs at the partner companies, resulting in contributing to new value creation.

Wisteriagen is also implementing our own drug discovery research focusing on specific targets that regulate gene expression associated with the cause of diseases in oncology and neurology. We believe in partnering as an important strategic choice to innovate and accelerate our pipeline.